Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.82 |
| ▸ | DRD3 | P35462 | 5/20 | 0.82 |
| ▸ | DRD4 | P21917 | 2/20 | 0.82 |
| ▸ | HTR1D | P28221 | 1/20 | 0.67 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.64 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025137 | 1.00 | DRD2 (0.82) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL2025138 | 1.00 | DRD2 (0.82) | DRD2DRD3DRD4HTR1DMTNR1A | |
| Hydrochloric Acid SCHEMBL2024400 | 0.99 | DRD2 (0.81) | DRD2DRD3DRD4HTR1DMTNR1A | |
| Azetidine SCHEMBL9242768 | 0.94 | DRD2 (0.73) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL8894131 | 0.92 | DRD2 (0.83) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL604798 | 0.90 | DRD2 (1.00) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL12072682 | 0.90 | DRD2 (1.00) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL7454456 | 0.90 | DRD2 (1.00) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL29802351 | 0.90 | DRD2 (1.00) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL1938120 | 0.90 | DRD2 (1.00) | DRD2DRD3DRD4MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516383-B1 | NEW AMINOTETRALINE DERIVATIVES | GMEINER PETER (DE) | 2017-05-03 | — | — | EP | disclosed |
| US-8691839-B2 | Aminotetraline derivatives | GMEINER PETER (DE) | 2014-04-08 | — | — | US | disclosed |
| US-20130331429-A1 | AMINOTETRALINE DERIVATIVES | GMEINER PETER (DE) | 2013-12-12 | — | — | US | disclosed |
| US-8586603-B2 | Aminotetraline derivatives | GMEINER PETER (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20120277262-A1 | NEW AMINOTETRALINE DERIVATIVES | GMEINER PETER (DE) | 2012-11-01 | — | — | US | disclosed |
| EP-2516383-A1 | NEW AMINOTETRALINE DERIVATIVES | Gmeiner, Peter (DE) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076708-A1 | NEW AMINOTETRALINE DERIVATIVES | GMEINER PETER (DE) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338873-A1 | New aminotetraline derivatives | Gmeiner, Peter (DE) | 2011-06-29 | — | — | EP | disclosed |
| WO-1994026703-A1 | NEW CENTRALLY ACTING 5-, 6-, 7-, AND 8-SUBSTITUTED SULPHONE ESTERS OF N-MONOSUBSTITUTED 2-AMINOTETRALINS AND RELATED STRUCTURES | DAMSMA-BLOEM, Anette, J. (NL) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277262-A1 | NEW AMINOTETRALINE DERIVATIVES | AADAT, ABAT, AANAT | DRD2 946/4885DRD3 1150/4885DRD4 1001/4885 |
| US-20130331429-A1 | AMINOTETRALINE DERIVATIVES | AADAT, ABAT, SLC1A2 | DRD2 415/4885DRD3 673/4885DRD4 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.